Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Rosetta Genomics's share price for the quarter that ended in Jun. 2017 was $2.3499. Rosetta Genomics's Shares Outstanding (EOP) for the quarter that ended in Jun. 2017 was 2.59 Mil. Therefore, Rosetta Genomics's market cap for the quarter that ended in Jun. 2017 was $6.08 Mil.
Rosetta Genomics's quarterly market cap
declined
from Jun. 2016 ($24.00 Mil) to Dec. 2016 ($9.29 Mil) and
declined
from Dec. 2016 ($9.29 Mil) to Jun. 2017 ($6.08 Mil).
Rosetta Genomics's annual market cap
declined
from Dec. 2014 ($26.58 Mil) to Dec. 2015 ($25.24 Mil) and
declined
from Dec. 2015 ($25.24 Mil) to Dec. 2016 ($9.29 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Rosetta Genomics's Enterprise Value for Today is $0.00 Mil.
Rosetta Genomics (OTCPK:ROSGQ) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Rosetta Genomics Market Cap Related Terms
Rosetta Genomics Market Cap Historical Data
* Premium members only.
The historical data trend for Rosetta Genomics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Rosetta Genomics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rosetta Genomics Market Cap vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Rosetta Genomics's Market Cap distribution charts can be found below:
* The bar in red indicates where Rosetta Genomics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Rosetta Genomics's Market Cap for the fiscal year that ended in Dec. 2016 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rosetta Genomics (ROSGQ) has a Market Cap of $0.00 Mil as of Jun. 26, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Rosetta Genomics and its competitors.
Is Rosetta Genomics' Market Cap too high?
Rosetta Genomics' current Market Cap is $0.00 Mil.
How does Rosetta Genomics' Market Cap compare to TEAR and IDTA?
Rosetta Genomics' Market Cap of $0.00 Mil can be compared against companies in the Medical Diagnostics & Research industry. The industry median Market Cap is 55.76. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Diagnostics & Research company?
The median Market Cap among Medical Diagnostics & Research companies is 55.76, based on 219 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Rosetta Genomics and its competitors. For the Medical Diagnostics & Research industry, the median Market Cap is 55.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rosetta Genomics's current Market Cap is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rosetta Genomics stock overvalued right now?
Rosetta Genomics (ROSGQ) has a current Market Cap of $0.00 Mil. The current Market Cap is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Rosetta Genomics (ROSGQ), the current Market Cap is $0.00 Mil as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROSGQ has been successfully added to your 